



Reimagine capacity for success

MabSelect™ Prisma Protein A chromatography resin

With enhanced properties of both the agarose base matrix and the Protein A ligand, MabSelect Prisma offers significantly increased capacity to help resolve bottlenecks in process-scale operations. Its higher binding capacity increases mass throughput per purification cycle, allowing for a more efficient use of existing equipment and ultimately enabling a delayed capital investment. The significantly improved alkaline stability ensures more efficient cleaning and sanitization to prevent carryover and enhance bioburden control in downstream mAb capture.

As part of the BioProcess™ family of products, MabSelect Prisma is developed and supported for large-scale manufacture of biopharmaceuticals.



gelifesciences.com/mabselectprisma

Designed for high-productive mAb capture


Increased dynamic binding capacity improves mass throughput and productivity. MabSelect PrismA allows binding of up to 80 g mAb/L resin at 6 min residence time, and up to 65 g mAb/L resin at 4 min residence time.

Purification performance of MabSelect PrismA is consistent with its predecessors MabSelect and MabSelect SuRe™ resins.

Enabling new standards for cleaning and sanitization

Improved alkaline stability enables more efficient cleaning and sanitization to help prevent growth of microorganisms and inactivate potential endotoxins, and the possibility of using NaOH as cleaning agent supports good process economy.

MabSelect PrismA exhibits more than 90% retained dynamic binding capacity after cleaning with 1.0 M NaOH or more than 95% retained dynamic binding capacity after cleaning with 0.5 M NaOH between runs for 150 cycles.



MabSelect PrismA exhibits significantly increased dynamic binding capacity compared with its predecessors.

Improving process efficiency


The high capacity of MabSelect PrismA allows for increased mass throughput per purification cycle, enabling productivity of current chromatography columns and systems to be improved without costly capital expenditures. MabSelect PrismA allows for up to 30% more product to be purified using current equipment.

Alternatively, the increased binding capacity can be used to decrease the resin volume required to achieve a given mass throughput.

Supply chain stability

A consistent, high-quality end product is depending on the use of equally consistent, high-quality manufacturing components. MabSelect PrismA is covered by GE's extensive security of supply program to ensure supply throughout your product's lifetime.

To ensure security of supply for critical raw materials, dual sourcing has been validated and implemented for the Protein A ligand and the agarose base matrix.



Relative remaining dynamic binding capacity using 1.0 M NaOH as cleaning agent for 15 min between cycles.

For more information and to request samples, visit gelifesciences.com/mabselectprisma

GE, the GE Monogram, BioProcess, MabSelect, and MabSelect SuRe are trademarks of General Electric Company.
© 2017 General Electric Company
GE Healthcare Bio-Sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden
For local office contact information, visit www.gelifesciences.com/contact
KA339190917FL